New Alzheimer’s Startup Funding Targets Both Treatment and Early Detection

Two recent deals illustrate this trend: a $17 million funding round for a non‑invasive ultrasound therapy in Japan, and a £550,000 pre‑seed round for a digital memory‑screening platform developed with Cambridge researchers.

1. Ultrasound Therapy Aiming to Slow Alzheimer’s Progression

Tokyo‑based Sound Wave Innovation recently raised roughly ¥2.65 billion (about $17 million) to complete a pivotal clinical trial of its LIPUS‑Brain device, which uses transcranial low‑intensity pulsed ultrasound (LIPUS) to treat early Alzheimer’s disease .

Unlike antibody drugs designed to remove amyloid proteins, LIPUS therapy targets the brain’s microvascular system. Research suggests the ultrasound stimulation may:

• Upregulate endothelial nitric oxide synthase (eNOS)
• Improve cerebral microcirculation
• Promote angiogenesis (formation of new blood vessels)

These mechanisms are hypothesized to support brain function and potentially slow cognitive decline .

Early studies indicated the therapy appeared safe and showed signals of cognitive benefit, which helped justify moving into larger clinical trials . The ongoing pivotal study is designed as a randomized, double‑blind, placebo‑controlled trial evaluating both safety and effectiveness in patients with early Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s .

If successful, LIPUS‑Brain could represent a non‑drug therapeutic option, an approach that may reduce some of the risks associated with pharmaceutical development while offering a minimally invasive intervention.

However, the therapy still needs strong clinical evidence before regulators or healthcare systems will adopt it.

2. Digital Screening for Earlier Dementia Detection

While Sound Wave Innovation targets treatment, Prema Cognition focuses on a different part of the Alzheimer’s care pathway: detecting cognitive decline earlier.

The London‑based startup raised £550,000 in a pre‑seed funding round led by SFC Capital, exceeding its initial £500,000 target due to investor demand . The funding will support:

• Expansion of clinical datasets
• Progress toward regulatory approval
• Broader deployment of the company’s digital screening platform

Prema’s core product, PREMAZ, is a digital cognitive assessment designed to detect subtle changes in memory function that may appear years before dementia symptoms become obvious . The test—developed in collaboration with researchers at the University of Cambridge Memory Lab—focuses on measuring the precision and quality of memory, rather than simply whether someone remembers information .

Digital tools like this could become valuable for:

• Primary‑care screening
• Remote cognitive monitoring
• Identifying candidates for clinical trials

However, while the funding and research collaborations are documented, independent clinical validation of PREMAZ’s effectiveness remains limited in publicly available evidence, meaning its diagnostic accuracy still needs stronger confirmation.

3. A Two‑Pronged Strategy Emerging in Alzheimer’s Innovation

Taken together, these deals illustrate a broader shift in how investors are approaching Alzheimer’s disease.

Instead of focusing only on blockbuster drugs, capital is increasingly distributed across the entire disease pathway:

• Early detection tools that identify cognitive decline sooner
• Digital diagnostics and biomarkers that track disease progression
• Device‑based therapies that target brain physiology
• Complementary treatments that may work alongside drugs

This approach reflects a growing consensus in research that earlier diagnosis and intervention are crucial for improving outcomes in neurodegenerative diseases.

4. Investor Confidence—With Significant Caveats

The investments also reveal cautious optimism in a field that has historically discouraged capital.

Alzheimer’s research faces two major structural challenges:

• Extremely high clinical trial failure rates for drugs
• A massive and growing global burden of neurological disease

Because of these risks, investors increasingly look for technologies that:

• Require smaller clinical trials than drugs
• Address earlier stages of disease
• Integrate with digital health systems
• Complement pharmaceutical therapies

Even so, funding announcements do not guarantee success. Both ultrasound therapy and digital screening platforms must still clear major milestones, including robust clinical validation, regulatory approval, reimbursement pathways, and real‑world healthcare adoption.

The Bottom Line

Recent funding rounds for Sound Wave Innovation and Prema Cognition highlight a new investment playbook in Alzheimer’s innovation: tackle the disease from multiple angles at once.

One company is testing whether ultrasound stimulation can slow cognitive decline, while the other aims to detect memory changes years earlier using digital testing. Together, they reflect a broader industry shift toward combining therapeutics, diagnostics, and digital health technologies in the fight against dementia.

Whether these approaches ultimately change patient outcomes will depend on rigorous clinical evidence—but the investments suggest that, despite decades of setbacks, investors still see brain health as one of the most important—and potentially transformative—frontiers in medicine.